NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
NOVAVAX INC (NVAX) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $72.59 per share as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2021-03-01
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $72.59.
- 2019-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $5.95.
- 2018-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.00.
- 2018-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value |
|---|---|
| 2020-12-31 | $72.59 10-K · filed 2021-03-01 |
| 2019-12-31 | $5.95 10-K · filed 2021-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-11 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-07 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-08 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 |
| 2017-12-31 | $4.99 10-Q · filed 2018-11-07 |
| 2017-09-30 | $4.99 10-Q · filed 2017-11-07 |
| 2017-06-30 | $4.99 10-Q · filed 2017-08-08 |
| 2017-03-31 | $4.99 10-Q · filed 2017-05-08 |
| 2016-12-31 | $4.99 10-K · filed 2018-03-14 |
| 2016-09-30 | $4.99 10-Q · filed 2016-11-09 |
| 2016-06-30 | $4.99 10-Q · filed 2016-08-09 |
| 2016-03-31 | $4.99 10-Q · filed 2016-05-05 |
| 2015-12-31 | $8.72 10-K · filed 2017-02-27 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 |
| 2015-06-30 | $4.48 10-Q · filed 2015-08-10 |
| 2015-03-31 | $4.48 10-Q · filed 2015-05-07 |
| 2014-12-31 | $4.48 10-K · filed 2016-02-29 |
| 2014-09-30 | $2.85 10-Q · filed 2014-11-06 |
| 2014-06-30 | $1.39 10-Q · filed 2014-08-07 |
| 2014-03-31 | $1.39 10-Q · filed 2014-05-08 |
| 2013-12-31 | $1.39 10-K · filed 2015-02-27 |
| 2013-09-30 | $1.39 10-Q · filed 2013-11-12 |
| 2013-06-30 | $1.39 10-Q · filed 2013-08-08 |
| 2013-03-31 | $1.39 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.39 10-K · filed 2014-03-12 |
| 2012-09-30 | $1.39 10-Q · filed 2012-11-09 |
| 2011-12-31 | $1.63 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |